US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SPYRE THERAPEUTICS INC

24.26

+0.43001.80%

Post-market: 24.260.00000.00%16:29 EDT

Volume:488.41K

Turnover:11.88M

Market Cap:1.88B

PE:-8.51

High:24.68

Open:23.79

Low:23.78

Close:23.83

52wk High:40.26

52wk Low:10.91

Shares:77.50M

Float Shares:63.83M

Volume Ratio:0.55

T/O Rate:0.77%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8512

EPS(LYR):-3.1802

ROE:-49.83%

ROA:-28.48%

PB:6.27

PE(LYR):-7.63

Loading ...

Overview Company News Filings

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Spyre Therapeutics (SYRE): Valuation Spotlight After New Clinical Data for Lead Anti-TL1A Therapy SPY072

Simply Wall St.

Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

Why Spyre Therapeutics (SYRE) Is Up 25.5% After $275 Million Equity Raise to Fund Pipeline Progress

Simply Wall St.

Spyre Therapeutics Closes $316.2 Million Public Offering

MT Newswires Live

Press Release: Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart

Spyre Therapeutics Inc - Expects $486.2 Mln in Cash and Equivalents as of Sept 30, 2025 - SEC Filing

THOMSON REUTERS

Spyre Therapeutics Reports Preliminary $486.2 Million in Cash and Securities as of September 30, 2025

Spyre Therapeutics Prices $275 Million Share Offering

MT Newswires Live

BRIEF-Spyre Therapeutics Announces Pricing Of $275 Million Public Offering Of Common Stock

Spyre Therapeutics Inc - Pricing of 14.9 Mln Shares at $18.50 per Share

THOMSON REUTERS

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

THOMSON REUTERS

Spyre Therapeutics Launches Public Offering

MT Newswires Live

BUZZ-Spyre Therapeutics falls after stock offering launch

Spyre Therapeutics announces common stock offering, no amount given

Spyre Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk

Halozyme Therapeutics Appoints Cortney Caudill as Chief Operating Officer

Spyre Therapeutics announces poster presentations at UEGW 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SYRE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SYRE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","market":"US","secType":"STK","nameCN":"SPYRE THERAPEUTICS INC","latestPrice":24.26,"timestamp":1761854400000,"preClose":23.83,"halted":0,"volume":488413,"hourTrading":{"tag":"盘后","latestPrice":24.26,"preClose":24.26,"latestTime":"16:29 EDT","volume":10493,"amount":254559.24,"timestamp":1761856197647},"delay":0,"floatShares":63829799,"shares":77495600,"eps":-2.851176,"marketStatus":"Not Yet Opened","change":0.43,"latestTime":"10-30 16:00:00 EDT","open":23.79,"high":24.68,"low":23.78,"amount":11884902.3511,"amplitude":0.037768,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.851176,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1761897600000},"marketStatusCode":0,"adr":0,"listingDate":1460001600000,"exchange":"NASDAQ","adjPreClose":23.83,"postHourTrading":{"tag":"盘后","latestPrice":24.26,"preClose":24.26,"latestTime":"16:29 EDT","volume":10493,"amount":254559.24,"timestamp":1761856197647},"volumeRatio":0.545692,"impliedVol":0.4249,"impliedVolPercentile":0.2249},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SYRE\",,,,,undefined,":{"symbol":"SYRE","floatShares":63829799,"roa":"-28.48%","roe":"-49.83%","lyrEps":-3.180151,"volumeRatio":0.545692,"shares":77495600,"dividePrice":0,"high":24.68,"amplitude":0.037768,"preClose":23.83,"low":23.78,"week52Low":10.91,"pbRate":"6.27","week52High":40.26,"institutionHeld":0,"latestPrice":24.26,"eps":-2.851176,"divideRate":0,"volume":488413,"delay":0,"ttmEps":-2.851176,"open":23.79,"prevYearClose":23.28,"prevWeekClose":23.37,"prevMonthClose":16.76,"prevQuarterClose":16.76,"fiveDayClose":22.37,"twentyDayClose":15.98,"sixtyDayClose":15.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SYRE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-05","symbol":"SYRE","fiscalQuarterEnding":"2025/06","expectedEps":-0.73,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754366400000,"reportTimeType":"post","actualEps":-0.49},{"market":"US","date":"2025-05-08","symbol":"SYRE","fiscalQuarterEnding":"2025/03","expectedEps":-0.76,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.74},{"market":"US","date":"2025-02-27","symbol":"SYRE","fiscalQuarterEnding":"2024/12","expectedEps":-1.1,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.81},{"market":"US","date":"2024-11-07","symbol":"SYRE","fiscalQuarterEnding":"2024/09","expectedEps":-0.8,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"post","actualEps":-1.36},{"market":"US","date":"2024-08-07","symbol":"SYRE","fiscalQuarterEnding":"2024/06","expectedEps":-0.9,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SYRE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SYRE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6154,"buy":0.3077,"hold":0.0769,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6154,"analysts":13,"updateTime":1758859200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SYRE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SYRE","date":"2025-10-29","current":-8.50877,"percent":0.023013,"low":-10.261647,"twenty":-6.670975,"median":-4.694469,"eighty":-3.696022,"high":-0.199399,"avg":-5.083699,"sd":1.798569,"marketCap":1909490450},"quantilePoints":[{"date":"2023-12-01","current":-1.902619,"twenty":-1.228042,"median":-0.216176,"eighty":-0.20611,"marketCap":560191990},{"date":"2023-12-08","current":-2.024974,"twenty":-2.048834,"median":-1.98164,"eighty":-0.890753,"marketCap":596217199},{"date":"2023-12-15","current":-1.815535,"twenty":-2.023412,"median":-1.966856,"eighty":-1.735642,"marketCap":534551743},{"date":"2023-12-22","current":-2.106706,"twenty":-2.023412,"median":-1.950531,"eighty":-1.82549,"marketCap":620281740},{"date":"2023-12-29","current":-2.507984,"twenty":-2.09023,"median":-1.996425,"eighty":-1.840422,"marketCap":738430643},{"date":"2024-01-05","current":-2.757559,"twenty":-2.278228,"median":-2.002935,"eighty":-1.873937,"marketCap":811913497},{"date":"2024-01-12","current":-2.567931,"twenty":-2.588728,"median":-2.024974,"eighty":-1.89995,"marketCap":756080936},{"date":"2024-01-19","current":-2.66458,"twenty":-2.653814,"median":-2.09023,"eighty":-1.902486,"marketCap":784537532},{"date":"2024-01-26","current":-3.303198,"twenty":-2.742878,"median":-2.292052,"eighty":-1.915254,"marketCap":972567189},{"date":"2024-02-02","current":-3.16373,"twenty":-3.116751,"median":-2.567931,"eighty":-1.947266,"marketCap":931503241},{"date":"2024-02-09","current":-2.89825,"twenty":-3.138772,"median":-2.61809,"eighty":-1.978684,"marketCap":853337655},{"date":"2024-02-16","current":-2.760005,"twenty":-3.112591,"median":-2.66458,"eighty":-1.997649,"marketCap":812633917},{"date":"2024-02-23","current":-2.496973,"twenty":-3.08641,"median":-2.66458,"eighty":-2.000865,"marketCap":735188752},{"date":"2024-03-01","current":-3.357028,"twenty":-3.117974,"median":-2.696389,"eighty":-2.009323,"marketCap":988416432},{"date":"2024-03-08","current":-4.14553,"twenty":-3.186241,"median":-2.748383,"eighty":-2.021849,"marketCap":1404464057},{"date":"2024-03-15","current":-4.473117,"twenty":-3.315921,"median":-2.757559,"eighty":-2.032927,"marketCap":1515447446},{"date":"2024-03-22","current":-4.253303,"twenty":-3.374155,"median":-2.84075,"eighty":-2.069838,"marketCap":1440976508},{"date":"2024-03-28","current":-3.948124,"twenty":-3.948124,"median":-2.884793,"eighty":-2.09023,"marketCap":1337584817},{"date":"2024-04-05","current":-3.822655,"twenty":-3.997689,"median":-2.933117,"eighty":-2.106706,"marketCap":1295077328},{"date":"2024-04-12","current":-4.169482,"twenty":-4.017483,"median":-2.950857,"eighty":-2.22293,"marketCap":1412578691},{"date":"2024-04-19","current":-3.844264,"twenty":-4.019298,"median":-3.071974,"eighty":-2.361175,"marketCap":1302398285},{"date":"2024-04-26","current":-3.508242,"twenty":-4.017483,"median":-3.149049,"eighty":-2.496973,"marketCap":1188557401},{"date":"2024-05-03","current":-4.312212,"twenty":-4.026871,"median":-3.180093,"eighty":-2.505537,"marketCap":1460934345},{"date":"2024-05-10","current":-4.183809,"twenty":-4.050631,"median":-3.290964,"eighty":-2.507984,"marketCap":1417432578},{"date":"2024-05-17","current":-4.180278,"twenty":-4.096445,"median":-3.334395,"eighty":-2.567931,"marketCap":1522561849},{"date":"2024-05-24","current":-3.614061,"twenty":-4.096445,"median":-3.364368,"eighty":-2.569154,"marketCap":1316331249},{"date":"2024-05-31","current":-4.872934,"twenty":-4.111605,"median":-3.38639,"eighty":-2.608303,"marketCap":1774844320},{"date":"2024-06-07","current":-4.694469,"twenty":-4.171641,"median":-3.527045,"eighty":-2.61809,"marketCap":1709842869},{"date":"2024-06-14","current":-4.393309,"twenty":-4.193693,"median":-3.59738,"eighty":-2.63375,"marketCap":1600152919},{"date":"2024-06-21","current":-3.360163,"twenty":-4.181695,"median":-3.573485,"eighty":-2.653814,"marketCap":1223855454},{"date":"2024-06-28","current":-3.277902,"twenty":-4.180281,"median":-3.545724,"eighty":-2.666048,"marketCap":1193893847},{"date":"2024-07-05","current":-3.553965,"twenty":-4.180278,"median":-3.545724,"eighty":-2.674367,"marketCap":1294442968},{"date":"2024-07-12","current":-4.13816,"twenty":-4.17596,"median":-3.564426,"eighty":-2.694186,"marketCap":1507221157},{"date":"2024-07-19","current":-4.113063,"twenty":-4.180278,"median":-3.593701,"eighty":-2.712782,"marketCap":1498080328},{"date":"2024-07-26","current":-4.387732,"twenty":-4.219183,"median":-3.614061,"eighty":-2.731867,"marketCap":1598121624},{"date":"2024-08-02","current":-3.651563,"twenty":-4.192391,"median":-3.674487,"eighty":-2.752053,"marketCap":1329990636},{"date":"2024-08-09","current":-6.773008,"twenty":-4.238871,"median":-3.689208,"eighty":-2.757559,"marketCap":1259650875},{"date":"2024-08-16","current":-7.111659,"twenty":-4.267009,"median":-3.707046,"eighty":-2.757559,"marketCap":1322633418},{"date":"2024-08-23","current":-6.972375,"twenty":-4.305721,"median":-3.744862,"eighty":-2.758537,"marketCap":1296729308},{"date":"2024-08-30","current":-7.851774,"twenty":-4.372067,"median":-3.796365,"eighty":-2.792303,"marketCap":1460280752},{"date":"2024-09-06","current":-7.655166,"twenty":-4.395693,"median":-3.839237,"eighty":-2.844176,"marketCap":1423715511},{"date":"2024-09-13","current":-8.038472,"twenty":-4.515004,"median":-3.909092,"eighty":-2.863261,"marketCap":1495003126},{"date":"2024-09-20","current":-8.260242,"twenty":-4.753435,"median":-3.923931,"eighty":-2.887484,"marketCap":1536248103},{"date":"2024-09-27","current":-7.800275,"twenty":-4.893011,"median":-3.931452,"eighty":-2.904612,"marketCap":1450702965},{"date":"2024-10-04","current":-7.980976,"twenty":-5.268067,"median":-3.990592,"eighty":-2.931282,"marketCap":1484309983},{"date":"2024-10-11","current":-7.857771,"twenty":-6.760445,"median":-4.004311,"eighty":-2.936176,"marketCap":1461396107},{"date":"2024-10-18","current":-8.969358,"twenty":-6.959266,"median":-4.01434,"eighty":-2.939112,"marketCap":1668130191},{"date":"2024-10-25","current":-9.530627,"twenty":-7.262959,"median":-4.019298,"eighty":-2.969942,"marketCap":1772515627},{"date":"2024-11-01","current":-9.303382,"twenty":-7.505129,"median":-4.04736,"eighty":-3.046528,"marketCap":1730252255},{"date":"2024-11-08","current":-9.47125,"twenty":-7.585076,"median":-4.070861,"eighty":-3.057293,"marketCap":2035390531},{"date":"2024-11-15","current":-6.988263,"twenty":-7.603794,"median":-4.087936,"eighty":-3.101825,"marketCap":1501791624},{"date":"2024-11-22","current":-7.566995,"twenty":-7.593388,"median":-4.106049,"eighty":-3.128495,"marketCap":1626162294},{"date":"2024-11-29","current":-7.766414,"twenty":-7.602508,"median":-4.133831,"eighty":-3.149049,"marketCap":1669017834},{"date":"2024-12-06","current":-7.397625,"twenty":-7.602508,"median":-4.146835,"eighty":-3.16373,"marketCap":1589764437},{"date":"2024-12-13","current":-6.589022,"twenty":-7.597044,"median":-4.169482,"eighty":-3.166361,"marketCap":1415994026},{"date":"2024-12-20","current":-6.517996,"twenty":-7.595055,"median":-4.180278,"eighty":-3.169847,"marketCap":1400730409},{"date":"2024-12-27","current":-6.466093,"twenty":-7.588386,"median":-4.182047,"eighty":-3.186241,"marketCap":1389576227},{"date":"2025-01-03","current":-6.651853,"twenty":-7.58308,"median":-4.215671,"eighty":-3.191991,"marketCap":1429496457},{"date":"2025-01-10","current":-6.135549,"twenty":-7.579794,"median":-4.247699,"eighty":-3.203592,"marketCap":1318541701},{"date":"2025-01-17","current":-5.632904,"twenty":-7.573901,"median":-4.253955,"eighty":-3.236074,"marketCap":1210522256},{"date":"2025-01-24","current":-5.900617,"twenty":-7.564263,"median":-4.27898,"eighty":-3.264517,"marketCap":1268054352},{"date":"2025-01-31","current":-6.280332,"twenty":-7.548513,"median":-4.304099,"eighty":-3.280514,"marketCap":1349655997},{"date":"2025-02-07","current":-6.187452,"twenty":-7.528128,"median":-4.345056,"eighty":-3.293411,"marketCap":1329695883},{"date":"2025-02-14","current":-6.26121,"twenty":-7.522652,"median":-4.382852,"eighty":-3.305947,"marketCap":1345546562},{"date":"2025-02-21","current":-5.815932,"twenty":-7.518271,"median":-4.394799,"eighty":-3.316941,"marketCap":1249855423},{"date":"2025-02-28","current":-5.708297,"twenty":-7.512359,"median":-4.473117,"eighty":-3.319102,"marketCap":1187428551},{"date":"2025-03-07","current":-5.647447,"twenty":-7.483663,"median":-4.605135,"eighty":-3.349687,"marketCap":1174770683},{"date":"2025-03-14","current":-5.227293,"twenty":-7.452562,"median":-4.749486,"eighty":-3.357028,"marketCap":1087371120},{"date":"2025-03-21","current":-5.264962,"twenty":-7.449529,"median":-4.833391,"eighty":-3.360163,"marketCap":1095206943},{"date":"2025-03-28","current":-5.198317,"twenty":-7.397625,"median":-4.89803,"eighty":-3.364368,"marketCap":1081343564},{"date":"2025-04-04","current":-3.706047,"twenty":-7.375771,"median":-4.833391,"eighty":-3.376602,"marketCap":770924425},{"date":"2025-04-11","current":-3.540883,"twenty":-7.371109,"median":-4.749486,"eighty":-3.378289,"marketCap":736567355},{"date":"2025-04-17","current":-3.671275,"twenty":-7.352984,"median":-4.694469,"eighty":-3.38477,"marketCap":763691357},{"date":"2025-04-25","current":-4.094327,"twenty":-7.328784,"median":-4.51381,"eighty":-3.412624,"marketCap":851693676},{"date":"2025-05-02","current":-4.378293,"twenty":-7.296115,"median":-4.473117,"eighty":-3.422161,"marketCap":910763726},{"date":"2025-05-09","current":-4.072986,"twenty":-7.269514,"median":-4.422481,"eighty":-3.450063,"marketCap":850985210},{"date":"2025-05-16","current":-4.384959,"twenty":-7.258044,"median":-4.393309,"eighty":-3.492778,"marketCap":916167055},{"date":"2025-05-23","current":-4.353184,"twenty":-7.252035,"median":-4.386346,"eighty":-3.506946,"marketCap":909528164},{"date":"2025-05-30","current":-4.491839,"twenty":-7.242247,"median":-4.381626,"eighty":-3.527827,"marketCap":938497873},{"date":"2025-06-06","current":-4.800924,"twenty":-7.228256,"median":-4.393309,"eighty":-3.543713,"marketCap":1003076183},{"date":"2025-06-13","current":-5.115786,"twenty":-7.156112,"median":-4.413455,"eighty":-3.545748,"marketCap":1068861565},{"date":"2025-06-20","current":-4.356073,"twenty":-7.062301,"median":-4.413455,"eighty":-3.549094,"marketCap":910131699},{"date":"2025-06-27","current":-4.627605,"twenty":-6.984824,"median":-4.413846,"eighty":-3.558149,"marketCap":966864047},{"date":"2025-07-03","current":-4.5525,"twenty":-6.978207,"median":-4.413846,"eighty":-3.566238,"marketCap":951172121},{"date":"2025-07-11","current":-4.610273,"twenty":-6.959266,"median":-4.434912,"eighty":-3.576816,"marketCap":963242833},{"date":"2025-07-18","current":-4.878917,"twenty":-6.905553,"median":-4.448509,"eighty":-3.590436,"marketCap":1019371645},{"date":"2025-07-25","current":-5.084011,"twenty":-6.899536,"median":-4.462257,"eighty":-3.592447,"marketCap":1062222673},{"date":"2025-08-01","current":-4.902026,"twenty":-6.889009,"median":-4.488402,"eighty":-3.59611,"marketCap":1024199930},{"date":"2025-08-08","current":-4.450911,"twenty":-6.843738,"median":-4.500505,"eighty":-3.597671,"marketCap":920510630},{"date":"2025-08-15","current":-4.924039,"twenty":-6.770823,"median":-4.509171,"eighty":-3.60188,"marketCap":1018360185},{"date":"2025-08-22","current":-4.900675,"twenty":-6.760445,"median":-4.52404,"eighty":-3.616232,"marketCap":1013528108},{"date":"2025-08-29","current":-4.883151,"twenty":-6.744059,"median":-4.5525,"eighty":-3.624946,"marketCap":1009904051},{"date":"2025-09-05","current":-4.962006,"twenty":-6.704732,"median":-4.610273,"eighty":-3.625072,"marketCap":1026212310},{"date":"2025-09-12","current":-4.731283,"twenty":-6.670975,"median":-4.650968,"eighty":-3.630649,"marketCap":978495552},{"date":"2025-09-19","current":-4.474275,"twenty":-6.670975,"median":-4.610273,"eighty":-3.651563,"marketCap":925342707},{"date":"2025-09-26","current":-4.558971,"twenty":-6.651853,"median":-4.590463,"eighty":-3.659766,"marketCap":942858985},{"date":"2025-10-03","current":-4.667031,"twenty":-6.651853,"median":-4.640746,"eighty":-3.671275,"marketCap":965207340},{"date":"2025-10-10","current":-6.182794,"twenty":-6.639187,"median":-4.66411,"eighty":-3.682866,"marketCap":1278688323},{"date":"2025-10-17","current":-6.495292,"twenty":-6.589022,"median":-4.675298,"eighty":-3.682866,"marketCap":1343317350},{"date":"2025-10-24","current":-8.382293,"twenty":-6.651853,"median":-4.679157,"eighty":-3.689208,"marketCap":1733575542},{"date":"2025-10-29","current":-9.232888,"twenty":-6.670975,"median":-4.694469,"eighty":-3.696022,"marketCap":1909490450}],"updateTime":1761874750652},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SYRE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579513488","title":"Spyre Therapeutics to Participate in Upcoming November Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2579513488","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579513488?lang=en_us&edition=fundamental","pubTime":"2025-10-30 04:05","pubTimestamp":1761768300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  29, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redef","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176866/0/en/Spyre-Therapeutics-to-Participate-in-Upcoming-November-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4581","BK4585","BK4539","SYRE","LENZ","XBI","BK4007","XLV","LABU","BK4588"],"gpt_icon":0},{"id":"2578689361","title":"Spyre Therapeutics (SYRE): Valuation Spotlight After New Clinical Data for Lead Anti-TL1A Therapy SPY072","url":"https://stock-news.laohu8.com/highlight/detail?id=2578689361","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578689361?lang=en_us&edition=fundamental","pubTime":"2025-10-26 04:22","pubTimestamp":1761423754,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics has just presented new data on its lead anti-TL1A therapy, SPY072, at the ACR Convergence Congress. The updates show the drug’s unique dosing profile, safety, and early support for ongoing development in rheumatic diseases.\nSee our latest analysis for Spyre Therapeutics.\nSparking investor attention, Spyre Therapeutics recently raised $275 million via a follow-on equity offering and has enjoyed a strong rebound. Its 30-day share price return is up 37.5%, marking a sharp turn...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-spotlight-after-new-clinic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/spyre-therapeutics-syre-valuation-spotlight-after-new-clinic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2577137245","title":"Spyre Therapeutics Reports Positive Six-Month Phase 1 Data for Anti-TL1A Antibody SPY072 in Rheumatic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2577137245","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577137245?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:00","pubTimestamp":1761307226,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. announced new scientific presentations at the upcoming American College of Rheumatology  Convergence Congress. The company will present follow-up data from its Phase 1 study of SPY072, an investigational anti-TL1A monoclonal antibody being developed for rheumatic diseases. Interim results indicate that SPY072 is well tolerated and exhibits a pharmacokinetic profile that may support maintenance dosing every three or six months. In addition, new preclinical data will be presented showing that anti-TL1A antibody treatment demonstrated efficacy comparable to or exceeding etanercept in a rodent model of collagen-induced arthritis. These data provide further support for the ongoing SKYWAY Phase 2 study evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The posters will be available for viewing during the ACR Convergence Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelli","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLmMH4j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2577351598","title":"Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577351598","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577351598?lang=en_us&edition=fundamental","pubTime":"2025-10-24 20:00","pubTimestamp":1761307200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct.  24, 2025  (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redef","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/24/3172754/0/en/Spyre-Therapeutics-Announces-Poster-Presentations-at-American-College-of-Rheumatology-ACR-Convergence-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","LENZ","BK4007","BK4107","SYRE","BK4139","BK4539","BK4110","AFG","ACR"],"gpt_icon":0},{"id":"2576778700","title":"Why Spyre Therapeutics (SYRE) Is Up 25.5% After $275 Million Equity Raise to Fund Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2576778700","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576778700?lang=en_us&edition=fundamental","pubTime":"2025-10-17 01:29","pubTimestamp":1760635789,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics recently completed a follow-on equity offering, raising approximately US$275 million by issuing about 14.9 million shares of common stock at US$18.50 per share, with the offering set to close around October 15, 2025.\nThis capital raise is expected to support the company’s clinical and preclinical progress in inflammatory bowel disease and rheumatic disease programs, with an updated liquidity position of about US$486.2 million as of September 30, 2025.\nWe’ll explore how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/why-spyre-therapeutics-syre-is-up-255-after-275-million-equi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/why-spyre-therapeutics-syre-is-up-255-after-275-million-equi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4585","BK4097","BK4215","SYRE","PRGS","LU2065732104.USD","BK4139","EQR"],"gpt_icon":0},{"id":"2575754645","title":"Spyre Therapeutics Closes $316.2 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2575754645","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575754645?lang=en_us&edition=fundamental","pubTime":"2025-10-16 05:13","pubTimestamp":1760562801,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said late Wednesday it closed its public offering of about 17.1 million common shares, including the full exercise of underwriters' overallotment option to buy 2.2 million shares, for gross proceeds of roughly $316.2 million.The shares were sold at $18.50 each, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LENZ","SYRE","BK4139","BK4539"],"gpt_icon":0},{"id":"2575756018","title":"Press Release: Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2575756018","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575756018?lang=en_us&edition=fundamental","pubTime":"2025-10-16 04:15","pubTimestamp":1760559300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Oct. 15, 2025  -- Spyre Therapeutics, Inc.  , a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease  and other immune-mediated diseases, today announced the closing of its previously announced underwritten public offering of 17,094,594 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,229,729 additional shares, at a public offering price per share of $18.50. The gross proceeds to Spyre from the offering were approximately $316.2 million before deducting underwriting discounts and commissions and other offering expenses payable by Spyre.Jefferies LLC, TD Securities  LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated acted as the joint book-running managers for the offering. Wedbush Securities Inc. acted as lead manager for the offering.Spyre Therapeutics is a clini","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","BK4007","USA","SYRE","IBD","BK4539"],"gpt_icon":0},{"id":"2575457245","title":"BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2575457245","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575457245?lang=en_us&edition=fundamental","pubTime":"2025-10-15 01:49","pubTimestamp":1760464164,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, WalmartEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nL6N3VV0KR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKA","CNX","PTRN","SYRE","NEXT","ATXS","NVDU","KKR","HUM","ANET","NVDS","NVA.AU","CRWD","CVX","ET","WMT","PII","DE","EDHL","APA","PAVS","LUV","BCRX","GM","NVAX","HPQ","PCH","WAB","BLK","JNJ","EQT","FAST","SNTI","DPZ","RYN","AQMS","OEC","EXPD","NVDD","2NVD.UK","XOM","WTI"],"gpt_icon":1},{"id":"2575296415","title":"Spyre Therapeutics Inc - Expects $486.2 Mln in Cash and Equivalents as of Sept 30, 2025  - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2575296415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575296415?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:26","pubTimestamp":1760437580,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nFWN3VV19D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2575729663","title":"Spyre Therapeutics Reports Preliminary $486.2 Million in Cash and Securities as of September 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575729663","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575729663?lang=en_us&edition=fundamental","pubTime":"2025-10-14 18:20","pubTimestamp":1760437201,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics Inc. announced that it expects to report approximately $486.2 million in cash, cash equivalents, and marketable securities as of September 30, 2025. This preliminary figure is based on the company's estimates for the quarter ended September 30, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL1LGwl9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2575261672","title":"Spyre Therapeutics Prices $275 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2575261672","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575261672?lang=en_us&edition=fundamental","pubTime":"2025-10-14 15:56","pubTimestamp":1760428607,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics  said late Monday it has priced a public offering of about 14.9 million shares at $18.50 each for expected gross proceeds of $275 million.The company granted the underwriters a 30-day option to purchase up to about 2.2 million additional shares.The offering is expected to close Wednesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","BK4007","SYRE","BK4539"],"gpt_icon":0},{"id":"2575230346","title":"BRIEF-Spyre Therapeutics Announces Pricing Of $275 Million Public Offering Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2575230346","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575230346?lang=en_us&edition=fundamental","pubTime":"2025-10-14 09:10","pubTimestamp":1760404256,"startTime":"0","endTime":"0","summary":"BRIEF-Spyre Therapeutics Announces Pricing Of $275 Million Public Offering Of Common StockOct 13 (Reuters) - Spyre Therapeutics Inc SYRE.O:SPYRE THERAPEUTICS ANNOUNCES PRICING OF $275.0 MILLION PUBLIC","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUA5L27QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2575832230","title":"Spyre Therapeutics Inc - Pricing of 14.9 Mln Shares at $18.50 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2575832230","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575832230?lang=en_us&edition=fundamental","pubTime":"2025-10-14 09:07","pubTimestamp":1760404024,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUA5L27QS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SYRE","BK4139"],"gpt_icon":0},{"id":"2575308312","title":"Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2575308312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575308312?lang=en_us&edition=fundamental","pubTime":"2025-10-14 09:07","pubTimestamp":1760404024,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUA5L27QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SYRE"],"gpt_icon":0},{"id":"2575280086","title":"Spyre Therapeutics Launches Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2575280086","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575280086?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:26","pubTimestamp":1760387217,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) said late Monday that it has commenced an underwritten public offering of its shares.Investors can also buy pre-funded warrants in lieu, the clinical-stage biotechnology firm said. It expects to grant underwriters a 30-day option to buy additional shares.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LENZ","SYRE","BK4139","BK4539"],"gpt_icon":0},{"id":"2575280294","title":"BUZZ-Spyre Therapeutics falls after stock offering launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2575280294","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575280294?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:17","pubTimestamp":1760386634,"startTime":"0","endTime":"0","summary":"BUZZ-Spyre Therapeutics falls after stock offering launch** Shares of Spyre Therapeutics SYRE.O fall 5.1% post-market to $17.96 as it seeks equity raise** Waltham, Massachusetts-based biotech, focused on treating inflammatory bowel disease and other immune-mediated diseases, commences offering of stock and pre-funded warrants without disclosing targeted deal size** Jefferies, TD Secs, Leerink and Stifel are joint bookrunners** Co has ~60.4 mln shares outstanding for about $1.1 bln market cap** SYRE shares on Mon finished down 1.2% at $18.92. Stock has risen about 13% over the past week, but is still down ~19% YTD** 12 of 13 analysts rate SYRE \"strong buy\" or \"buy\",  1 rates \"hold\" and median PT is $56, per LSEG data","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL6N3VU0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SYRE","BK4559","BK4127","JEF"],"gpt_icon":0},{"id":"2575802882","title":"Spyre Therapeutics announces common stock offering, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2575802882","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575802882?lang=en_us&edition=fundamental","pubTime":"2025-10-14 04:05","pubTimestamp":1760385927,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of issuing comm...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-common-stock-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-common-stock-offering-no-amount-given-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4539","BK4007","SYRE"],"gpt_icon":0},{"id":"2574607621","title":"Spyre Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2574607621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574607621?lang=en_us&edition=fundamental","pubTime":"2025-10-10 01:37","pubTimestamp":1760031420,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics, Inc  is currently at $21.14, up $3.46 or 19.54%. --Would be highest close since Feb. 24, 2025, when it closed at $21.26. --On pace for largest percent increase since Nov. 28, 2023, when it rose 20.73%. --Currently up two consecutive days; up 31.93% over this period. --Down 9.21% year-to-date; on pace for worst year since 2022, when it fell 90.53%. --Down 92.95% from its all-time closing high of $299.75 on April 8, 2016. --Down 22.35% from 52 weeks ago , when it closed at $27.22. --Traded as high as $21.25; highest intraday level since Feb. 26, 2025, when it hit $21.50. --Up 20.19% at today's intraday high; largest intraday percent increase since March 1, 2024, when it rose as much as 20.23%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","SYRE","BK4539","BK4139"],"gpt_icon":0},{"id":"2573985691","title":"Halozyme Therapeutics Appoints Cortney Caudill as Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2573985691","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573985691?lang=en_us&edition=fundamental","pubTime":"2025-10-07 04:58","pubTimestamp":1759784339,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics Inc. has appointed Cortney Caudill as Senior Vice President and Chief Operating Officer, effective immediately. Caudill joined Halozyme in October 2023 as Senior Vice President, Chief Operations Officer. She previously held leadership roles at Aeglea Biotherapeutics, Cambrex Bioscience, Genentech, Samsung Biologics, and other life sciences companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 06, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL9dyb6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","SYRE","BK4139"],"gpt_icon":0},{"id":"2573579610","title":"Spyre Therapeutics announces poster presentations at UEGW 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573579610","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573579610?lang=en_us&edition=fundamental","pubTime":"2025-10-06 01:10","pubTimestamp":1759684217,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics (SYRE) announced scientific presentations at the European Gastroenterology Week, UEGW, Congress. “We are excited to share follow...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-poster-presentations-at-uegw-2025-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/spyre-therapeutics-announces-poster-presentations-at-uegw-2025-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SYRE","LENZ","BK4539","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}]}}